JOIN OUR TEAM

Topic: Pharmaceuticals

Data Over Supply

Some Data May be Cheap, but Could Prove Expensive: the Untold Stories

Companies are confronted on a daily, even hourly, basis with the need for data about their own businesses and intelligence about their competitors. Easily available, secondary data may be adequate for the purpose provided that they are reliable. Unfortunately, that is the essence of the problem: is secondary data reliable?

Complex Strategies Based on Questionable Data
All too often companies spend an inordinate amount of time and effort constructing complex strategies based on questionable, unvalidated data. Companies prepared to spend hundreds of millions of dollars on an acquisition appear ready (or resigned) to pay for good legal, tax, and environmental advice, but may base the commercial analysis on casual data found on various unsubstantiated websites.

Know More »
Shaking Things Up: How Smart Companies Overcome Industry Stagnation through M&A

Shaking Things Up: How Smart Companies Overcome Industry Stagnation through M&A

Every industry goes through a similar lifecycle, from emerging to evolving, then reaching maturity and finally, decline. Early on, new players enter the market, taking advantage of the broad opportunities that exist during the emerging and evolving phases and often driving stellar growth in the process.

On the road to maturity, consolidation inevitably shifts the balance of market share into the hands of a few key players, just as we’ve seen over the last few decades in the chemicals industry and more recently in consumer products, such as the U.S. toothpastes market, in which three companies control about 80% of the market share. This consolidation typically occurs through M&A, which can breathe new life into stalled portfolios and re-ignite revenue growth. But how do you know when it’s time to pursue this strategy? And what kind of specific challenges can M&A help solve?

Know More »
Play Video
Play Video